RxDoctor Payments Data

Fredda Jackson

Acute Care · Parsippany, NJNPI 1487968012

Payments from drug & device makers

$1,504in general payments, 2019–2025

Across 63 payments — averaging $23.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$528
  • Teva Pharmaceuticals USA, Inc.$236
  • Supernus Pharmaceuticals, Inc.$201
  • E.r. Squibb & Sons, L.L.C.$197
  • AbbVie$173
  • Otsuka America Pharmaceutical, Inc.$45
  • plus $123 from 6 others

What the payments were for

  • Food & beverage$1,504100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,504 in reported general payments places this provider in the 80th percentile of 656 acute care providers in New Jersey.

See all acute care providers in New Jersey

Medicare billing

Part B allowed, 2024
$6,624
Medicare patients
59
Services billed
128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate13$49,760
Aripiprazole118$5,825
Olanzapine158$3,636
Divalproex Sodium ErDivalproex Sodium26$3,168
Lurasidone Hcl33$2,753
Chlorpromazine Hcl15$2,200
Paliperidone ErPaliperidone17$1,932
Divalproex Sodium68$1,790
Trazodone Hcl117$1,610
Benztropine Mesylate112$1,585
Haloperidol94$1,498
Fluoxetine Hcl75$1,288
Ziprasidone Hcl11$1,192
Oxcarbazepine24$1,192
Buspirone Hcl49$1,179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$22$619102 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 656 acute care providers in New Jersey.

Other acute care in Parsippany

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →